These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27539393)

  • 1. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
    Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
    Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
    BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Total, PTEN
    Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
    Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
    Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
    Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    Goldkorn A; Tangen C; Plets M; Bsteh D; Xu T; Pinski JK; Ingles S; Triche TJ; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Dorff TB; Lerner SP; Thompson I; Agarwal N
    JAMA Netw Open; 2024 Oct; 7(10):e2437871. PubMed ID: 39374015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
    Punnoose EA; Ferraldeschi R; Szafer-Glusman E; Tucker EK; Mohan S; Flohr P; Riisnaes R; Miranda S; Figueiredo I; Rodrigues DN; Omlin A; Pezaro C; Zhu J; Amler L; Patel P; Yan Y; Bales N; Werner SL; Louw J; Pandita A; Marrinucci D; Attard G; de Bono J
    Br J Cancer; 2015 Oct; 113(8):1225-33. PubMed ID: 26379078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.
    Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
    Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
    JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
    Crespo M; van Dalum G; Ferraldeschi R; Zafeiriou Z; Sideris S; Lorente D; Bianchini D; Rodrigues DN; Riisnaes R; Miranda S; Figueiredo I; Flohr P; Nowakowska K; de Bono JS; Terstappen LW; Attard G
    Br J Cancer; 2015 Mar; 112(7):1166-74. PubMed ID: 25719830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
    Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
    Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
    Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
    [No Abstract]   [Full Text] [Related]  

  • 19. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
    Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
    Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.
    Sieuwerts AM; Onstenk W; Kraan J; Beaufort CM; Van M; De Laere B; Dirix LY; Hamberg P; Beeker A; Meulenbeld HJ; Creemers GJ; van Weerden WM; Jenster GW; Nieuweboer AJM; Mathijssen RHJ; de Wit R; Martens JWM; Sleijfer S
    Mol Oncol; 2019 Aug; 13(8):1795-1807. PubMed ID: 31180178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.